Adalimumab biosimilar - Bionovis/The Instituto Vital Brazil

Drug Profile

Adalimumab biosimilar - Bionovis/The Instituto Vital Brazil

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator Bionovis; The Instituto Vital Brazil
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 08 Jun 2015 Clinical trials in Ankylosing spondylitis in Brazil (SC) before June 2015
  • 08 Jun 2015 Clinical trials in Crohn's disease in Brazil (SC) before June 2015
  • 08 Jun 2015 Clinical trials in Plaque psoriasis in Brazil (SC) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top